Enrolling Studies

The research team at ARC is currently managing several different clinical studies. Are you interested in a particular study opportunity? Information about current study opportunities currently enrolling patients can be found below. Both ARC patients and non-ARC patients who fit the trial eligibility requirements are welcome.

• Abbvie 3110-305-002 Pediatric Migraine Clinical Study

  A phase III, multicenter, randomized, double-blind, placebo-controlled, single-attack study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of oral Ubrogepant in the acute treatment of migraine with or without aura in children and adolescents (ages 6-17).

  About the Study

• BaxDuo Pacific Chronic Kidney Disease (CKD) Clinical Study

  A phase III, randomized, double-blind, active-controlled study intended to assess the efficacy, safety, and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease (CKD) progression and cardiovascular events in participants with CKD and high blood pressure.

  About the Study

• Chronic Spontaneous Urticaria (CSU) Clinical Study

  A multi-center, phase 2b, randomized, placebo-controlled, dose-ranging study evaluating the efficacy and safety of EV0756 in subjects with moderate to severe CSU (chronic spontaneous urticaria).

  About the Study

• ENABLE Multiple Sclerosis (MS) Clinical Study

  A long-term observational registry study for patients with multiple sclerosis (MS) to collect real-world data on BRIUMVI (infusion medication) and assess efficacy, safety, and tolerability of medication.

  About the Study

• Sanofi PSK05 Pediatric Pneumococcal Clinical Study

  A phase III, randomized, modified double-blind, active-controlled, parallel-group, two-arm study to investigate the safety of a four-dose regimen of a 21-valent pneumococcal conjugate vaccine in healthy infants and toddlers.

  About the Study

• VAX 31-201 Pediatric Pneumococcal Clinical Study

  A phase II, randomized-double, active-controlled, dose-finding clinical study to evaluate the safety, tolerability, and immunogenicity of the investigational vaccine, VAX-31, in healthy infants. Participants are given four doses at two, four, six, and 12-15 months of age, alongside routine pediatric vaccines. VAX-31 is designed to protect against 31 serotypes of pneumococcus bacteria, compared to the usual 20 serotypes covered by current pneumococcal conjugate vaccines (PCVs).

  About the Study